STING Agonist-18 (Compound 1a) serves as a key synthetic intermediate for constructing antibody-drug conjugates (ADCs) such as Trastuzumab-based conjugates. This small molecule is utilized in research to develop immunotherapeutic ADCs, with applications studied in both in vitro assays and in vivo tumor models to evaluate targeted STING pathway activation.